Klaus Elenius

N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration.

Endothelial cell-matrix interactions.

Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor.

Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.

Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.

Intra- and extracellular signaling by endothelial neuregulin-1.

Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient.

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.

Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.

Role of ErbB4 in breast cancer.

ErbB4 and its isoforms: patentable drug targets?

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.

Potential of ErbB4 antibodies for cancer therapy.

Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth.

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

Cell death or survival promoted by alternative isoforms of ErbB4.

Function of ERBB4 is determined by alternative splicing.

ErbB4 modulates tubular cell polarity and lumen diameter during kidney development.

Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.

Proteolytic processing of ErbB4 in breast cancer.

Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example.

Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.

CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.

ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.

High frequency of BRAF V600E mutations in ameloblastoma.

Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland.

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.

ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis.

Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.

Human Metaplastic Breast Carcinoma and Decorin.

Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases.

SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase.

Gamma-secretase-dependent signaling of receptor tyrosine kinases.

Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target.

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.

ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos.

Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling.

An unbiased screen for activating epidermal growth factor receptor mutations.

Decorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin cDNA Transduction on Carcinoma Cells.

Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.

Genetic and functional implications of an exonic TRIM55 variant in heart failure.